Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma. Tiago M, Purwin TJ, Stefanski CD, da Silva RO, et al. J Clin Invest 2025;135:e178446.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tiago M, Purwin TJ, Stefanski CD, da Silva RO, et al. Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma. J Clin Invest 2025;135:e178446.
PMID: 40955663